--- title: "Pelacarsen | PepTracker Pro" url: https://peptrackerpro.com/peptides/pelacarsen description: "A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Pelacarsen Medium Evidence A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026. Aliases TQJ230 +5 more Evidence Medium Evidence Last Updated 2026-08-06 Reading Time 4 min ## What It Is Pelacarsen is a first-in-class, once-monthly subcutaneous antisense oligonucleotide (ASO) being developed by Ionis Pharmaceuticals and Novartis to lower lipoprotein(a) — commonly written Lp(a) — a genetically determined, causal risk factor for heart attack, stroke, peripheral artery disease, and calcific aortic valve stenosis. Roughly one in five people worldwide inherit high Lp(a), and unlike LDL cholesterol it cannot be meaningfully changed by diet, exercise, statins, or PCSK9 inhibitors; there is currently no approved therapy that specifically and robustly lowers it. Pelacarsen attacks the problem at its source: it is a GalNAc-conjugated (LICA, Ligand-Conjugated Antisense) oligonucleotide that is taken up by liver cells and binds the messenger RNA for apolipoprotein(a) — the LPA gene product that defines the Lp(a) particle — triggering its degradation so the liver makes far less apo(a) and assembles far fewer Lp(a) particles. In Phase 2, the 80 mg monthly dose reduced Lp(a) by roughly 80% and brought 98% of participants below the guideline risk threshold of 50 mg/dL. The compound (formerly IONIS-APO(a)-LRx / TQJ230) was discovered by Ionis using its LICA platform and licensed to Novartis for worldwide development in 2019. The pivotal Phase 3 Lp(a)HORIZON trial (NCT04023552) enrolled 8,323 patients with established cardiovascular disease and Lp(a) ≥ 70 mg/dL into a global, double-blind, placebo-controlled study, testing whether lowering Lp(a) with 80 mg pelacarsen monthly reduces major adverse cardiovascular events (expanded MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization). Crucially, Lp(a)HORIZON is the first cardiovascular outcomes trial for any Lp(a)-targeting therapy, so its readout will not only decide pelacarsen's fate but also test the central hypothesis that lowering Lp(a) prevents cardiovascular events — validating or challenging an entire emerging drug class that includes the siRNAs olpasiran, lepodisiran, and zerlasiran. Topline results were originally guided for 2025 and then to a mid-2026 window, with the readout imminent as of mid-2026 and Novartis planning regulatory submissions to follow. Pelacarsen is investigational and not approved anywhere; it is a clinical-stage prescription medicine, not a supplement or research chemical. Also known as: TQJ230, IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, ISIS 681257, apo(a)-LRx, Lp(a)-lowering antisense oligonucleotide ## Regulatory Status Investigational — not approved Pelacarsen is not approved for any use anywhere. It is being evaluated in the pivotal Phase 3 Lp(a)HORIZON cardiovascular outcomes trial (NCT04023552; 8,323 patients with established CVD and Lp(a) ≥ 70 mg/dL), the first-ever outcomes trial for an Lp(a)-lowering therapy. Topline data were originally expected in 2025, then guided to a mid-2026 window; the readout is imminent as of mid-2026, with Novartis planning regulatory submissions thereafter. Licensed by Novartis from Ionis for exclusive worldwide development, manufacturing, and commercialization. Effective: 2026 View FDA Source (https://ir.ionis.com/news-releases/news-release-details/ionis-announces-enrollment-completion-phase-3-lpa-horizon) ## Why Researchers Study It Pelacarsen is the compound that will answer the field's biggest open question in cardiovascular medicine: does lowering lipoprotein(a) actually prevent heart attacks and strokes? Lp(a) has been recognized for decades as an independent, inherited, causal risk factor for cardiovascular disease, but no therapy has ever been able to lower it specifically — and no outcomes trial has ever tested whether doing so helps. Pelacarsen's Lp(a)HORIZON trial is the first such experiment. Researchers study it both as a potentially first-in-class treatment for the ~20% of people born with high Lp(a) and as a proof-of-concept for the entire Lp(a)-lowering class (which also includes the siRNAs olpasiran, lepodisiran, and zerlasiran). A positive readout would establish Lp(a) as a modifiable target and open a new front in preventive cardiology; a null result would reshape how the field thinks about the risk factor. ## Proposed Mechanisms - GalNAc-conjugated (LICA) antisense oligonucleotide taken up selectively by hepatocytes - Binds and triggers degradation of apolipoprotein(a) [LPA] messenger RNA in the liver, reducing apo(a) synthesis - Fewer apo(a) molecules means the liver assembles far fewer Lp(a) particles, lowering circulating Lp(a) by ~80% - Aims to reduce the atherogenic, pro-inflammatory, and thrombogenic cardiovascular risk carried by Lp(a) independent of LDL cholesterol ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 2 (dose-ranging, elevated Lp(a) with CVD) | Adults with established cardiovascular disease and elevated Lp(a) | Monthly pelacarsen produced dose-dependent Lp(a) lowering of up to ~80%; the 80 mg monthly dose selected for Phase 3 reduced Lp(a) below the guideline risk threshold (<50 mg/dL) in 98% of participants | Source: https://ir.ionis.com/news-releases/news-release-details/ionis-announces-enrollment-completion-phase-3-lpa-horizon | | Phase 3 (Lp(a)HORIZON, cardiovascular outcomes, NCT04023552) | 8,323 adults with established CVD and Lp(a) ≥ 70 mg/dL — global, randomized, double-blind, placebo-controlled | First-ever CV outcomes trial for an Lp(a)-lowering drug; primary endpoint is superiority vs placebo in reducing expanded MACE (CV death, non-fatal MI, non-fatal stroke, urgent coronary revascularization). Fully enrolled; topline readout expected 2026 | Source: https://clinicaltrials.gov/study/NCT04023552 | | Mechanism / target validation | Human genetics and epidemiology of lipoprotein(a) | Elevated Lp(a) is an independent, inherited, causal risk factor for coronary heart disease, stroke, peripheral artery disease, and aortic stenosis, affecting roughly 20% of people; it is not lowered by lifestyle, statins, or PCSK9 inhibitors — establishing the rationale for a specific apo(a)-lowering therapy | Source: https://www.acc.org/latest-in-cardiology/articles/2025/12/01/01/feature-lipoprotein-a | ## Commonly Discussed Benefits Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Disease Modification: https://peptrackerpro.com/benefits/disease-modification Researching Pelacarsen? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=pelacarsen) ## Safety & Cautions - Investigational — not approved for any use anywhere; efficacy on cardiovascular events has not yet been demonstrated (Lp(a)HORIZON topline pending in 2026) - Robust Lp(a) lowering (~80%) is established, but whether that lowering translates into fewer heart attacks and strokes is exactly what the pending outcomes trial is designed to test - A prescription clinical-stage biologic administered by subcutaneous injection under medical supervision — not a supplement, nootropic, or research chemical - Any 'pelacarsen', 'TQJ230', or 'apo(a)-LRx' offered by a vendor is unverified and not a legitimate source of this investigational medicine - Not interchangeable with LDL-lowering drugs (statins, PCSK9 inhibitors); it targets Lp(a), a distinct, genetically determined lipoprotein ## Comparisons See how Pelacarsen compares to related peptides: Pelacarsen vs Enlicitide: https://peptrackerpro.com/compare/pelacarsen-vs-enlicitide Pelacarsen vs Eplontersen: https://peptrackerpro.com/compare/pelacarsen-vs-eplontersen Pelacarsen vs Inclisiran: https://peptrackerpro.com/compare/pelacarsen-vs-inclisiran Pelacarsen vs Lepodisiran: https://peptrackerpro.com/compare/pelacarsen-vs-lepodisiran Pelacarsen vs Muvalaplin: https://peptrackerpro.com/compare/pelacarsen-vs-muvalaplin Pelacarsen vs Obicetrapib: https://peptrackerpro.com/compare/pelacarsen-vs-obicetrapib Pelacarsen vs Olezarsen: https://peptrackerpro.com/compare/pelacarsen-vs-olezarsen Pelacarsen vs Olpasiran: https://peptrackerpro.com/compare/pelacarsen-vs-olpasiran Pelacarsen vs Plozasiran: https://peptrackerpro.com/compare/pelacarsen-vs-plozasiran Pelacarsen vs Solbinsiran: https://peptrackerpro.com/compare/pelacarsen-vs-solbinsiran Pelacarsen vs Sotatercept: https://peptrackerpro.com/compare/pelacarsen-vs-sotatercept Pelacarsen vs Vutrisiran: https://peptrackerpro.com/compare/pelacarsen-vs-vutrisiran Pelacarsen vs WVE-007: https://peptrackerpro.com/compare/pelacarsen-vs-wve-007 Pelacarsen vs Zerlasiran: https://peptrackerpro.com/compare/pelacarsen-vs-zerlasiran Pelacarsen vs Zilebesiran: https://peptrackerpro.com/compare/pelacarsen-vs-zilebesiran Pelacarsen vs Ziltivekimab: https://peptrackerpro.com/compare/pelacarsen-vs-ziltivekimab Pelacarsen vs Zodasiran: https://peptrackerpro.com/compare/pelacarsen-vs-zodasiran Pelacarsen vs Donidalorsen: https://peptrackerpro.com/compare/pelacarsen-vs-donidalorsen ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Ionis — Enrollment Completion of Phase 3 Lp(a)HORIZON Cardiovascular Outcomes Study of Pelacarsen (trial design, 80 mg monthly, 8,325 participants, Phase 2 data) PubMed (https://ir.ionis.com/news-releases/news-release-details/ionis-announces-enrollment-completion-phase-3-lpa-horizon) 2. [2] Lp(a)HORIZON — Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events (ClinicalTrials.gov NCT04023552) PubMed (https://clinicaltrials.gov/study/NCT04023552) 3. [3] Lipoprotein(a): An Independent Risk Factor for CV Disease — American College of Cardiology PubMed (https://www.acc.org/latest-in-cardiology/articles/2025/12/01/01/feature-lipoprotein-a) 4. [4] Pelacarsen: Mechanism of Action and Lp(a)-Lowering Effect — Journal of Clinical Lipidology PubMed (https://www.lipidjournal.com/article/S1933-2874(25)00322-8/fulltext) 5. [5] 2026 Cardiovascular Catalysts: Lp(a) on the Horizon — BioCentury PubMed (https://www.biocentury.com/article/658135/2026-cardiovascular-catalysts-lp-a-on-the-horizon) ### Keep researching in the app - Log Pelacarsen to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=pelacarsen Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Enlicitide High Evidence An oral PCSK9 inhibitor peptide that reduced LDL cholesterol by 57% in Phase 3 trials — matching injectable monoclonal antibodies in efficacy while offering once-daily pill convenience. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/enlicitide \+ Compare: https://peptrackerpro.com/compare?select=enlicitide Track in App: https://app.peptrackerpro.com/?add=enlicitide ### Eplontersen High Evidence An approved, once-monthly, self-administered subcutaneous GalNAc-conjugated antisense oligonucleotide (ASO) from Ionis and AstraZeneca that treats transthyretin-mediated (ATTR) amyloidosis by lowering the liver's production of transthyretin (TTR). Transthyretin is a liver-made transport protein that can misfold and deposit as amyloid in nerves and the heart; eplontersen is a short synthetic strand of chemically modified DNA/RNA that binds TTR messenger RNA and directs its enzymatic (RNase H1) degradation before the protein is made, cutting circulating TTR by roughly 80%. A triantennary N-acetylgalactosamine (GalNAc) tag delivers it to liver cells, allowing a low-dose 45 mg injection just once a month via autoinjector or pre-filled syringe. Marketed as Wainua (US) and Wainzua (EU), it was FDA-approved in December 2023 for the polyneuropathy of hereditary ATTR amyloidosis (ATTRv-PN) on the strength of the NEURO-TTRansform trial, and is now approved in more than 20 countries. Eplontersen is the antisense (ASO) counterpart to the siRNA drug vutrisiran (Amvuttra): both silence TTR, and both were tested in ATTR cardiomyopathy - but where vutrisiran's HELIOS-B trial succeeded on top of a stabilizer background, eplontersen's much larger CARDIO-TTRansform cardiomyopathy trial missed its primary endpoint in July 2026, with a benefit seen only in the prespecified monotherapy subgroup. It is a GalNAc-ASO sibling of Ionis's olezarsen and pelacarsen and the second-generation successor to the earlier, non-GalNAc TTR antisense drug inotersen (Tegsedi). Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular View Details: https://peptrackerpro.com/peptides/eplontersen \+ Compare: https://peptrackerpro.com/compare?select=eplontersen Track in App: https://app.peptrackerpro.com/?add=eplontersen ### Inclisiran High Evidence An approved, twice-yearly subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Novartis (originally discovered by Alnylam) that lowers LDL cholesterol by silencing PCSK9 (proprotein convertase subtilisin/kexin type 9), the liver protein that destroys LDL receptors. By switching off PCSK9 production inside hepatocytes, inclisiran leaves more LDL receptors on the liver surface to pull LDL cholesterol out of the blood - achieving roughly a 50% LDL reduction with an injection given only twice a year after a loading dose. Marketed as Leqvio, it was the first siRNA medicine approved for a chronic cardiovascular condition: the EU cleared it in December 2020 and the FDA in December 2021, and in July 2025 the FDA expanded the U.S. label to first-line monotherapy, dropping the requirement that it be added on top of a statin. Its Phase 3 ORION-9, ORION-10 and ORION-11 trials established the LDL benefit; a large cardiovascular outcomes program (VICTORION-2-PREVENT and others) is still running to test whether that LDL lowering prevents heart attacks and strokes. Inclisiran is the approved, real-world proof-of-concept for the GalNAc-siRNA cardiometabolic platform that newer investigational agents like zodasiran, solbinsiran, olpasiran and plozasiran build on. View Details: https://peptrackerpro.com/peptides/inclisiran \+ Compare: https://peptrackerpro.com/compare?select=inclisiran Track in App: https://app.peptrackerpro.com/?add=inclisiran ### Lepodisiran Medium Evidence An investigational, long-duration injectable small interfering RNA (siRNA) from Eli Lilly that lowers lipoprotein(a) [Lp(a)] by nearly 94% by silencing the LPA gene in the liver. A single dose keeps Lp(a) suppressed for a year or more, and its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes trial to include people who have not yet had a cardiovascular event. View Details: https://peptrackerpro.com/peptides/lepodisiran \+ Compare: https://peptrackerpro.com/compare?select=lepodisiran Track in App: https://app.peptrackerpro.com/?add=lepodisiran ### Muvalaplin Medium Evidence The first oral, small-molecule inhibitor of lipoprotein(a) [Lp(a)] formation, from Eli Lilly. Instead of silencing a gene, muvalaplin is a once-daily pill that physically blocks apolipoprotein(a) from binding apolipoprotein B — the first step in building an Lp(a) particle. In its Phase 2 KRAKEN trial (published in JAMA, 2024) it cut Lp(a) by up to ~86% (placebo-adjusted) and, as of 2026, is the only Lp(a)-lowering drug that is both oral and already enrolling a large Phase 3 cardiovascular outcomes trial (MOVE-Lp(a)). View Details: https://peptrackerpro.com/peptides/muvalaplin \+ Compare: https://peptrackerpro.com/compare?select=muvalaplin Track in App: https://app.peptrackerpro.com/?add=muvalaplin ### Obicetrapib Medium Evidence An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026. View Details: https://peptrackerpro.com/peptides/obicetrapib \+ Compare: https://peptrackerpro.com/compare?select=obicetrapib Track in App: https://app.peptrackerpro.com/?add=obicetrapib ### Olezarsen High Evidence An FDA-approved subcutaneous antisense oligonucleotide (ASO) from Ionis Pharmaceuticals, branded Tryngolza, that lowers triglycerides by silencing the messenger RNA for apolipoprotein C-III (apoC-III). Self-injected once a month, it was the first-ever therapy approved for familial chylomicronemia syndrome (FCS) on December 19, 2024, and on June 24, 2026 it became the first and only treatment approved to reduce both triglycerides and the risk of acute pancreatitis in the far larger severe hypertriglyceridemia (sHTG) population. View Details: https://peptrackerpro.com/peptides/olezarsen \+ Compare: https://peptrackerpro.com/compare?select=olezarsen Track in App: https://app.peptrackerpro.com/?add=olezarsen ### Olpasiran Medium Evidence An investigational, once-every-12-weeks injectable small interfering RNA (siRNA) from Amgen that lowers lipoprotein(a) [Lp(a)] by up to ~97% by silencing the LPA gene in the liver. Its Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial (~7,000 patients) is one of the pivotal readouts — due December 2026 — that will help decide whether lowering Lp(a) prevents heart attacks and strokes. View Details: https://peptrackerpro.com/peptides/olpasiran \+ Compare: https://peptrackerpro.com/compare?select=olpasiran Track in App: https://app.peptrackerpro.com/?add=olpasiran ### Plozasiran High Evidence An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population. View Details: https://peptrackerpro.com/peptides/plozasiran \+ Compare: https://peptrackerpro.com/compare?select=plozasiran Track in App: https://app.peptrackerpro.com/?add=plozasiran ### Solbinsiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program. View Details: https://peptrackerpro.com/peptides/solbinsiran \+ Compare: https://peptrackerpro.com/compare?select=solbinsiran Track in App: https://app.peptrackerpro.com/?add=solbinsiran ### Sotatercept High Evidence Sotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Energy: https://peptrackerpro.com/benefits/energy Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/sotatercept \+ Compare: https://peptrackerpro.com/compare?select=sotatercept Track in App: https://app.peptrackerpro.com/?add=sotatercept ### Vutrisiran High Evidence An approved, quarterly (once-every-three-months) subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam that treats transthyretin-mediated (ATTR) amyloidosis by silencing the TTR gene in the liver. Transthyretin is a liver-made transport protein that can misfold and pile up as amyloid deposits in nerves and, critically, the heart; vutrisiran uses RNA interference (RNAi) to degrade both mutant and wild-type TTR messenger RNA before the protein is made, lowering circulating TTR by roughly 80% and starving the amyloid of its raw material. Marketed as Amvuttra, it was first FDA-approved in June 2022 for the polyneuropathy of hereditary ATTR amyloidosis (HELIOS-A), and in March 2025 the FDA expanded the label to ATTR cardiomyopathy (ATTR-CM) of wild-type or hereditary disease - making vutrisiran the first RNAi therapeutic shown to reduce cardiovascular death and cardiovascular events, on the strength of the HELIOS-B outcomes trial. It shares the exact GalNAc-siRNA delivery platform that underlies the cardiometabolic RNAi medicine inclisiran and the investigational agents olpasiran, lepodisiran, zerlasiran, zilebesiran, zodasiran, solbinsiran and plozasiran, and it is the direct successor to Alnylam's earlier intravenous TTR siRNA patisiran (Onpattro). Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/vutrisiran \+ Compare: https://peptrackerpro.com/compare?select=vutrisiran Track in App: https://app.peptrackerpro.com/?add=vutrisiran ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/wve-007 \+ Compare: https://peptrackerpro.com/compare?select=wve-007 Track in App: https://app.peptrackerpro.com/?add=wve-007 ### Zerlasiran Medium Evidence An investigational, long-acting injectable small interfering RNA (siRNA) from Silence Therapeutics that lowers lipoprotein(a) [Lp(a)] by more than 80% by silencing the LPA gene in the liver. Dosed only every 16–24 weeks, it produced durable ~90% reductions in its Phase 2 ALPACAR-360 trial (published in JAMA, 2024); as of 2026 the company is seeking a partner before starting its Phase 3 cardiovascular outcomes study. View Details: https://peptrackerpro.com/peptides/zerlasiran \+ Compare: https://peptrackerpro.com/compare?select=zerlasiran Track in App: https://app.peptrackerpro.com/?add=zerlasiran ### Zilebesiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam Pharmaceuticals and Roche/Genentech that lowers blood pressure by silencing angiotensinogen (AGT), the single upstream precursor of the renin-angiotensin-aldosterone system (RAAS). Designed for dosing as infrequently as once or twice a year, it is the first RNА interference (RNAi) therapeutic developed for hypertension. In Phase 2 KARDIA-1 and KARDIA-2 trials it produced durable, clinically meaningful reductions in systolic blood pressure sustained for up to 6 months from a single dose, and in 2025 it advanced into the large Phase 3 ZENITH cardiovascular outcomes trial. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/zilebesiran \+ Compare: https://peptrackerpro.com/compare?select=zilebesiran Track in App: https://app.peptrackerpro.com/?add=zilebesiran ### Ziltivekimab Medium Evidence An investigational, fully human monoclonal antibody that neutralizes the pro-inflammatory cytokine interleukin-6 (IL-6) to test whether lowering vascular inflammation - independently of cholesterol - can prevent heart attacks, strokes and cardiovascular death. Given as a low-volume, once-monthly 15 mg subcutaneous injection (half-life ~57 days), ziltivekimab was originally developed by Corvidia Therapeutics and acquired by Novo Nordisk in 2020 for up to $2.1 billion. It is the flagship clinical test of the 'residual inflammatory risk' hypothesis that grew out of the CANTOS trial of the IL-1 beta antibody canakinumab: the idea that many high-risk patients keep having cardiovascular events because of ongoing inflammation (marked by high-sensitivity C-reactive protein, hsCRP) even when LDL cholesterol is well controlled. In the Phase 2 RESCUE trial ziltivekimab cut hsCRP by up to ~92%, and it advanced into three large Phase 3 cardiovascular outcomes trials - ZEUS, HERMES and ARTEMIS. On July 31, 2026, Novo Nordisk announced that the pivotal ZEUS trial (>6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation) MISSED its primary endpoint: despite clear target engagement (large falls in free IL-6 and hsCRP), ziltivekimab did not reduce major adverse cardiovascular events versus placebo (hazard ratio 0.99, 95% CI 0.88-1.11). The heart-failure trial HERMES and the post-heart-attack trial ARTEMIS continue, with readouts expected in the first half of 2027. Ziltivekimab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. Inflammation: https://peptrackerpro.com/benefits/inflammation Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management View Details: https://peptrackerpro.com/peptides/ziltivekimab \+ Compare: https://peptrackerpro.com/compare?select=ziltivekimab Track in App: https://app.peptrackerpro.com/?add=ziltivekimab ### Zodasiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Arrowhead Pharmaceuticals that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made regulator of fat metabolism. By switching off ANGPTL3 production, zodasiran deeply reduces triglycerides, remnant cholesterol and LDL cholesterol through a pathway that does not depend on the LDL receptor - making it especially relevant for people, such as those with homozygous familial hypercholesterolemia (HoFH), whose LDL receptors barely work. In the Phase 2b ARCHES-2 trial (NEJM 2024) it produced durable, dose-dependent reductions in triglycerides, remnant cholesterol and ANGPTL3, and in the Phase 2 GATEWAY study it lowered LDL cholesterol by about 40% in HoFH. It is now in the Phase 3 YOSEMITE trial in HoFH, which completed enrollment in July 2026. View Details: https://peptrackerpro.com/peptides/zodasiran \+ Compare: https://peptrackerpro.com/compare?select=zodasiran Track in App: https://app.peptrackerpro.com/?add=zodasiran ### Donidalorsen High Evidence An FDA-approved RNA-targeted therapy that prevents hereditary angioedema (HAE) attacks by turning down production of a single blood protein rather than blocking it after it forms. Donidalorsen (brand name Dawnzera) is a GalNAc-conjugated antisense oligonucleotide (ASO) taken up by liver cells, where it binds the messenger RNA for prekallikrein (the gene KLKB1) and triggers its degradation, lowering circulating prekallikrein. Because prekallikrein sits at the top of the kallikrein-kinin cascade that generates bradykinin - the peptide that drives the swelling of HAE - reducing it prevents the runaway bradykinin surges responsible for painful, sometimes life-threatening attacks. It was approved by the U.S. FDA on August 21, 2025 as the first and only RNA-targeted prophylactic medicine for HAE, for routine prevention of attacks in adults and children aged 12 and older. It is given as an 80 mg subcutaneous self-injection by autoinjector once every four weeks, with the option to move to once every eight weeks in well-controlled patients. In the pivotal Phase 3 OASIS-HAE trial, donidalorsen reduced monthly HAE attacks by about 81% versus placebo over 24 weeks, and in the OASISplus switch study most patients who moved from other long-term prophylaxis preferred donidalorsen. Donidalorsen is a prescription biologic developed by Ionis Pharmaceuticals and administered under specialist care - not a supplement or research chemical. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/donidalorsen \+ Compare: https://peptrackerpro.com/compare?select=donidalorsen Track in App: https://app.peptrackerpro.com/?add=donidalorsen ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Pelacarsen", "description": "A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026.", "url": "https://peptrackerpro.com/peptides/pelacarsen", "lastReviewed": "2026-08-06", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Pelacarsen", "item": "https://peptrackerpro.com/peptides/pelacarsen" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People who have learned they have high lipoprotein(a) and want to know if a treatment is coming?", "acceptedAnswer": { "@type": "Answer", "text": "Pelacarsen is a research peptide studied in preclinical models. A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026." } }, { "@type": "Question", "name": "Patients with early or recurrent heart attacks or strokes despite well-controlled LDL cholesterol?", "acceptedAnswer": { "@type": "Answer", "text": "Pelacarsen is a research peptide studied in preclinical models. A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026." } }, { "@type": "Question", "name": "Clinicians and researchers tracking the first cardiovascular outcomes trial for an Lp(a)-lowering therapy?", "acceptedAnswer": { "@type": "Answer", "text": "Pelacarsen is a research peptide studied in preclinical models. A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026." } }, { "@type": "Question", "name": "Those comparing pelacarsen (an antisense oligonucleotide) with the Lp(a)-lowering siRNAs olpasiran, lepodisiran, and zerlasiran?", "acceptedAnswer": { "@type": "Answer", "text": "Pelacarsen is a research peptide studied in preclinical models. A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026." } } ] } ] ```